M1 Kliniken AG

  • WKN: A0STSQ
  • ISIN: DE000A0STSQ8
  • Land: Deutschland

Nachricht vom 22.11.2018 | 08:00

M1 Kliniken AG opens further specialist centres: Market leader in beauty medicine remains on course for expansion in 2018

DGAP-News: M1 Kliniken AG / Key word(s): Expansion

22.11.2018 / 08:00
The issuer is solely responsible for the content of this announcement.



M1 Kliniken AG opens further specialist centres: Market leader in beauty medicine remains on course for expansion in 2018

- Expansion 2018 on schedule: The number of specialist centres will increase by more than 30%

- Entry into aesthetic dentistry market well received by patients

- Conditions created for further significant increases in sales in the coming year


Berlin, 22.11.2018 - M1 Kliniken AG (ISIN: DE000A0STSQ8), the number 1 in the field of beauty medicine in Germany, continues its expansion course in 2018. 4 new specialist centres have been opened so far this year. Two more are to follow by the end of the year. The M1 Group will thus operate a total of 24 specialist centres for aesthetic treatments by the end of 2018. The increase of more than 30% compared to the previous year is in line with corporate planning. M1 Kliniken AG is thus creating the conditions for a further significant increase in sales in the coming year.

While M1 already opened its second location in Munich and Hamburg, the company premiered in Dresden. In October, the M1 Med Beauty specialist centre opened at the idyllic Jüdenhof 9 square in the state capital of Saxony. The modern premises are located directly in the historic old town near the famous Frauenkirche, Dresden's landmark.

In addition, the first treatment centre for aesthetic dentistry was opened in Berlin in early 2018. With the brand "M1 Dental", the company offers bleaching treatments, ceramic veneers for permanently straight and white teeth as well as transparent braces for 'inconspicuous' tooth correction. Also in this range M1 sets landmarks in quality and price. The range of services is to be expanded step by step.

"Beauty medicine has arrived in the middle of society and the demand is constantly increasing. We are pleased that we can make a contribution to market penetration with our high-quality treatments at fair prices," says Patrick Brenske, member of the Management Board of M1 Kliniken AG. "Our entry into the dental market was very well received by our patients and we will start our nationwide expansion in the coming months".

About M1 Kliniken AG
M1 Kliniken AG is the leading private provider of beauty medicine health services in Germany. In the aesthetic and surgical field, the group offers products and services of the highest quality. Under the brands "M1 Med Beauty" and "M1 Dental", a network of currently 22 outpatient specialist centres for beauty treatments and a specialist surgical clinic is operated. With six operating theatres and 35 beds, the Schlossklinik for Plastic and Aesthetic Surgey in Berlin is one of the largest and most modern facilities of its kind in Europe. In addition, the Group markets high-quality products to doctors, pharmacies and wholesalers. www.m1-kliniken.de

Details on the M1 Kliniken AG share
Subscribed capital: EUR 17,500,000
Class of shares: Bearer shares
ISIN: DE000A0STSQ8 * WKN: A0STSQ * Ticker symbol: M12

Contact us
M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
Phone: +49 (0)30 347 47 44 14
E-mail: ir@m1-kliniken.de



22.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

UniDevice AG: Rekord-Ergebnis in 2018

Nach starkem Schlussspurt hat die UniDevice AG in 2018 Umsatz und Ergebnis deutlich gesteigert. Der B2B-Broker für hochpreisige Smartphones sollte auch künftig eine hohe Nachfrage verzeichnen und von der Ausnutzung unterschiedlicher Preisniveaus in den verschiedenen Ländern profitieren. Der Umsatz soll 2019 auf mindestens 380 Mio. € und in 2020 auf mindestens 410 Mio. € ansteigen, nachdem 2018 317 Mio. € erreicht wurden. Bei einem ermittelten Kursziel in Höhe von 2,35 € lautet das Rating KAUFEN.

News im Fokus

Linde plc: Linde plc Investor & Media Conference Call - Information

22. Februar 2019, 19:38

Aktueller Webcast

Ströer SE & Co. KGaA

Vorläufige Geschäftszahlen 2018

26. Februar 2019

Aktuelle Research-Studie

Sanochemia Pharmazeutika AG

Original-Research: Sanochemia Pharmazeutika AG (von Sphene Capital GmbH): Buy

21. Februar 2019